Angelo Di Leo

List of Publications by Year in Descending Order

172 papers	11,591 citations	53 h-index	106 g-index
186 ext. papers	13,716 ext. citations	6.3 avg, IF	5.72 L-index

#	Paper	IF	Citations
172	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. *Cancers*, **2021**, 13,	6.6	2
171	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. *Cancers*, **2021**, 13,	6.6	5
170	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. *Cancer Discovery*, **2021**, 11, 2796-2811	24.4	10
169	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. *Journal of Clinical Oncology*, **2021**, 39, 3938-3958	2.2	11
168	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. *Clinical Cancer Research*, **2021**, 27, 504-512	12.9	3
167	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. *Cancer Treatment Reviews*, **2021**, 93, 102136	14.4	7
166	Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. *Npj Breast Cancer*, **2021**, 7, 11	7.8	6
165	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. *Cancers*, **2021**, 13,	6.6	4
164	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. *Journal of Clinical Oncology*, **2021**, 39, 2720-2731	2.2	3
163	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. *Clinical Cancer Research*, **2020**, 26, 2131-2139	12.9	22
162	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. *Breast Cancer Research and Treatment*, **2020**, 181, 347-359	4.4	7
161	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. *International Journal of Cancer*, **2020**, 146, 1917-1929	7.5	3
160	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. *Npj Breast Cancer*, **2019**, 5, 26	7.8	8
159	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. *Cancer Treatment Reviews*, **2019**, 74, 29-34	14.4	11
158	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. *Npj Breast Cancer*, **2019**, 5, 5	7.8	176
157	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. *Clinical Breast Cancer*, **2019**, 19, 392-398	3	11
156	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. *Breast Cancer Research*, **2019**, 21, 71	8.3	14

155	A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. *Breast Cancer*, **2019**, 26, 703-711	3.4	4
154	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). *European Journal of Cancer*, **2019**, 114, 55-66	7.5	18
153	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. *Journal of Clinical Oncology*, **2019**, 37, 105-114	2.2	38
152	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. *Journal of Clinical Oncology*, **2019**, 37, 386-395	2.2	11
151	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. *British Journal of Cancer*, **2019**, 120, 959-967	8.7	3
150	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet, The*, **2019**, 393, 1440-1452	40	137
149	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. *Pharmacogenomics Journal*, **2019**, 19, 556-563	3.5	20
148	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncology, The*, **2019**, 20, 371-382	21.7	200
147	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. *Frontiers in Oncology*, **2019**, 9, 666	5.3	69
146	Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution. *Breast Journal*, **2019**, 25, 1225-1229	1.2	
145	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. *Journal of Clinical Oncology*, **2019**, 37, 538-538	2.2	
144	The Emerging Role of Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. *Cancers*, **2019**, 11,	6.6	27
143	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919891608	5.4	2
142	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. *Breast*, **2019**, 48 Suppl 1, S81-S84	3.6	1
141	Immune Infiltration in Invasive Lobular Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 768-776	9.7	55
140	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 316-324	4	37
139	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. *Breast*, **2018**, 38, 144-149	3.6	8
138	Metabolomics in breast cancer: A decade in review. *Cancer Treatment Reviews*, **2018**, 67, 88-96	14.4	65

137	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. *Breast Cancer Research and Treatment*, **2018**, 170, 351-360	4.4	5
136	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. *Breast Cancer Research and Treatment*, **2018**, 170, 329-341	4.4	10
135	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. *Anticancer Research*, **2018**, 38, 4839-4845	2.3	4
134	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 122-137	59.2	270
133	The role of abemaciclib in treatment of advanced breast cancer. *Therapeutic Advances in Medical Oncology*, **2018**, 10, 1758835918776925	5.4	11
132	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. *International Journal of Oncology*, **2018**, 52, 424-432	4.4	5
131	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. *Journal of Clinical Oncology*, **2018**, 36, 1048-1048	2.2	1
130	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. *Journal of Clinical Oncology*, **2018**, 36, 503-503	2.2	11
129	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. *Journal of Clinical Oncology*, **2018**, 36, 570-570	2.2	
128	Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3 **2018**,		2
127	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. *Lancet Oncology, The*, **2018**, 19, 27-39	21.7	413
126	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 87-100	21.7	228
125	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 127-138	21.7	62
124	ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. *BMC Genomics*, **2018**, 19, 960	4.5	10
123	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. *Npj Breast Cancer*, **2018**, 4, 41	7.8	30
122	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. *Npj Breast Cancer*, **2018**, 4, 38	7.8	40
121	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. *BMC Cancer*, **2018**, 18, 932	4.8	2
120	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1385-1393	21.7	195

119	In Reply to Belkacemi and Tsoutsou. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 467-468	4	
118	Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population. *Clinical Cancer Research*, **2017**, 23, 1422-1431	12.9	54
117	Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2017**, 72, 922-928	6.4	19
116	Recurrence dynamics of breast cancer according to baseline body mass index. *European Journal of Cancer*, **2017**, 87, 10-20	7.5	27
115	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *Journal of Clinical Oncology*, **2017**, 35, 3638-3646	2.2	699
114	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. *Breast Care*, **2017**, 12, 304-308	2.4	38
113	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. *Breast*, **2017**, 34 Suppl 1, S13-S18	3.6	6
112	RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. *Journal of the National Cancer Institute*, **2017**, 109, 1	9.7	2
111	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2) metastatic breast cancer (mBC) (TREnd trial).. *Journal of Clinical Oncology*, **2017**, 35, 1002-1002	2.2	8
110	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. *Journal of Clinical Oncology*, **2016**, 34, 936-44	2.2	14
109	Metabolomics in Breast Cancer: Current Status and Perspectives. *Advances in Experimental Medicine and Biology*, **2016**, 882, 217-34	3.6	21
108	Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes. *Breast*, **2016**, 27, 189	3.6	
107	Using CTCs for pharmacogenomic analysis. *Pharmacological Research*, **2016**, 106, 92-100	10.2	4
106	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. *Critical Reviews in Oncology/Hematology*, **2016**, 100, 57-68	7	13
105	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. *Oncotarget*, **2016**, 7, 68012-68022	3.3	79
104	Serum metabolomics as biomarkers to differentiate early from metastatic disease and predict relapse in elderly colorectal cancer (CRC) patients.. *Journal of Clinical Oncology*, **2016**, 34, 10042-10042	2.2	
103	Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. *Oncotarget*, **2016**, 7, 26107-19	3.3	116
102	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 5755-5764	12.9	11

101	Circulating Tumour Cells as Liquid Biopsy in Breast Cancer: Advancing from Prognostic to Predictive Potential. *Current Breast Cancer Reports*, **2015**, 7, 53-58	0.8	
100	Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. *European Journal of Cancer*, **2015**, 51, 1481-9	7.5	26
99	Continued value of adjuvant anthracyclines as treatment for early breast cancer. *Lancet Oncology, The*, **2015**, 16, e362-9	21.7	40
98	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. *Journal of Clinical Oncology*, **2015**, 33, 1574-83	2.2	112
97	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. *BMC Medicine*, **2015**, 13, 46	11.4	23
96	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Annals of Oncology*, **2015**, 26, 1533-46	10.3	1122
95	Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*, **2015**, 20, 474-82	5.7	102
94	New approaches for improving outcomes in breast cancer in Europe. *Breast*, **2015**, 24, 321-30	3.6	37
93	Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. *Breast*, **2015**, 24 Suppl 2, S136-42	3.6	14
92	Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. *EPMA Journal*, **2015**, 6, 17	8.8	10
91	A multifactorial PCR-based Consensus Signature by analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. *Npj Breast Cancer*, **2015**, 1, 15003	7.8	3
90	Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. *Journal of Clinical Oncology*, **2015**, 33, 1680-7	2.2	47
89	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. *Nature Reviews Clinical Oncology*, **2015**, 12, 541-52	19.4	80
88	Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. *Molecular Oncology*, **2015**, 9, 128-39	7.9	72
87	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. *Molecular Oncology*, **2015**, 9, 749-57	7.9	129
86	A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. *Cancer Treatment Reviews*, **2015**, 41, 94-104	14.4	18
85	Meta-analysis of clinical outcomes to second-line endocrine therapy for visceral and non-visceral metastases.. *Journal of Clinical Oncology*, **2015**, 33, 568-568	2.2	
84	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2014**, 32, 3307-29	2.2	185

83	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. *Breast*, **2014**, 23, 473-81	3.6	10
82	Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?. *Cancers*, **2014**, 6, 684-707	6.6	25
81	Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. *Current Opinion in Oncology*, **2014**, 26, 568-75	4.2	28
80	International study on inter-reader variability for circulating tumor cells in breast cancer. *Breast Cancer Research*, **2014**, 16, R43	8.3	41
79	Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. *Journal of the National Cancer Institute*, **2014**, 106, djt337	9.7	181
78	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. *Psycho-Oncology*, **2014**, 23, 173-82	3.9	41
77	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. *Molecular Oncology*, **2014**, 8, 508-19	7.9	49
76	In silico analysis of a multifactorial consensus signature (ConSig) for predicting response to anthracycline (A)-based neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients (pts).. *Journal of Clinical Oncology*, **2014**, 32, 1025-1025	2.2	1
75	Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 640-640	2.2	
74	A prospective study to evaluate the Vulnerable Elders Survey-13 (VES-13) as a tool to identify frail older cancer patients (pts).. *Journal of Clinical Oncology*, **2014**, 32, 9546-9546	2.2	
73	Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. *Journal of Clinical Oncology*, **2014**, 32, 630-630	2.2	
72	Targeting triple negative breast cancer: is p53 the answer?. *Cancer Treatment Reviews*, **2013**, 39, 541-50	14.4	89
71	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *Journal of Clinical Oncology*, **2013**, 31, 860-7	2.2	1023
70	The continued evidence from overviews: what is the clinical utility?. *Breast*, **2013**, 22 Suppl 2, S8-11	3.6	1
69	HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. *Cancer Treatment Reviews*, **2013**, 39, 947-57	14.4	54
68	Adjuvant chemotherapy: which patient? What regimen?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 3-8	7.1	3
67	DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. *Oncologist*, **2013**, 18, 1063-73	5.7	64
66	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. *Breast Cancer Research and Treatment*, **2013**, 138, 149-55	4.4	10

65	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. *Future Oncology*, **2013**, 9, 1477-87	3.6	9
64	The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. *PLoS ONE*, **2013**, 8, e62543	3.7	28
63	Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?. *Ecancermedicalscience*, **2013**, 7, 299	2.7	14
62	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. *Breast*, **2012**, 21, 336-42	3.6	9
61	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. *Breast Cancer Research*, **2012**, 14, R70	8.3	47
60	Dissecting the heterogeneity of triple-negative breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 1879-87	2.2	304
59	Metabolomics in cancer: a bench-to-bedside intersection. *Critical Reviews in Oncology/Hematology*, **2012**, 84, 1-7	7	67
58	Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. *Molecular Oncology*, **2012**, 6, 437-44	7.9	66
57	Targeting Metabolomics in Breast Cancer. *Current Breast Cancer Reports*, **2012**, 4, 249-256	0.8	4
56	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. *Breast Cancer Research and Treatment*, **2012**, 134, 333-43	4.4	94
55	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. *Cancer*, **2012**, 118, 2603-14	6.4	220
54	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. *Breast Cancer Research and Treatment*, **2012**, 134, 283-9	4.4	80
53	The nutritional risk in oncology: a study of 1,453 cancer outpatients. *Supportive Care in Cancer*, **2012** , 20, 1919-28	3.9	108
52	Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. *International Journal for Quality in Health Care*, **2012**, 24, 411-8	1.9	20
51	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. *Journal of Clinical Oncology*, **2012** , 30, LBA671-LBA671	2.2	34
50	Predictive molecular markers of anthracycline effectiveness in early breast cancer. *European Journal of Cancer, Supplement*, **2011**, 9, 16-21	1.6	1
49	Uncovering the metabolomic fingerprint of breast cancer. *International Journal of Biochemistry and Cell Biology*, **2011**, 43, 1010-20	5.6	71
48	Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. *European Journal of Cancer*, **2011**, 47 Suppl 3, S370-2	7.5	10

47	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. *Lancet Oncology, The*, **2011**, 12, 1134-42	21.7	141
46	Adjuvant systemic treatment for individual patients with triple negative breast cancer. *Breast*, **2011** , 20 Suppl 3, S135-41	3.6	12
45	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. *Current Breast Cancer Reports*, **2011**, 3, 24-33	0.8	
44	Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. *Future Oncology*, **2011**, 7, 173-86	3.6	4
43	Multifactorial approach to predicting resistance to anthracyclines. *Journal of Clinical Oncology*, **2011**, 29, 1578-86	2.2	143
42	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. *Tumori*, **2011**, 97, 690-2	1.7	11
41	Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. *Journal of Clinical Oncology*, **2010**, 28, 4594-600	2.2	467
40	Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. *Clinical Cancer Research*, **2010**, 16, 1281-8	12.9	29
39	Ode to a past emperor. *Journal of Clinical Oncology*, **2010**, 28, 2938-40	2.2	
38	Breast cancer assessment tools and optimizing adjuvant therapy. *Nature Reviews Clinical Oncology*, **2010**, 7, 725-32	19.4	75
37	Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. *Nature Reviews Clinical Oncology*, **2010**, 7, 22-36	19.4	87
36	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. *Current Medical Research and Opinion*, **2010**, 26, 767-75	2.5	13
35	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. *Breast Cancer Research and Treatment*, **2010**, 119, 145-53	4.4	117
34	Re-searching anthracycline therapy. *Breast Cancer Research and Treatment*, **2010**, 123, 171-5	4.4	7
33	Management of triple negative breast cancer. *Breast*, **2010**, 19, 312-21	3.6	148
32	Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. *Journal of Clinical Oncology*, **2009**, 27, 3908-15	2.2	131
31	Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. *Journal of the National Cancer Institute*, **2009**, 101, 1735-6; author reply 1736-7	9.7	4
30	Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. *Journal of Clinical Oncology*, **2009**, 27, 5552-8	2.2	43

29	Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. *Journal of Clinical Oncology*, **2009**, 27, 720-5	2.2	19
28	Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?. *Breast*, **2009**, 18 Suppl 3, S18-24	3.6	4
27	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. *Breast Cancer Research and Treatment*, **2009**, 118, 523-30	4.4	183
26	Taxanes in the elderly: can we gain as much and be less toxic?. *Critical Reviews in Oncology/Hematology*, **2009**, 70, 262-71	7	16
25	The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. *Cancer Treatment Reviews*, **2009**, 35, 662-7	14.4	23
24	Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. *Breast Cancer Research*, **2009**, 11, 205	8.3	55
23	Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. *Radiotherapy and Oncology*, **2009**, 90, 116-21	5.3	12
22	Predicting anthracycline benefit: have we made any progress?. *Current Opinion in Oncology*, **2009**, 21, 507-15	4.2	8
21	Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). *Clinical Breast Cancer*, **2008**, 8, 453-6	3	43
20	Topoisomerase II alpha as a marker predicting anthracyclinesPactivity in early breast cancer patients: ready for the primetime?. *European Journal of Cancer*, **2008**, 44, 2791-8	7.5	30
19	HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. *Clinical Cancer Research*, **2008**, 14, 7861-70	12.9	137
18	Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. *Clinical Cancer Research*, **2008**, 14, 4511-6	12.9	51
17	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 5544-52	2.2	363
16	Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. *Journal of the National Cancer Institute*, **2008**, 100, 121-33	9.7	123
15	Metabolomics: available results, current research projects in breast cancer, and future applications. *Journal of Clinical Oncology*, **2007**, 25, 2840-6	2.2	199
14	Gastric Cancer Metastatic to the Pituitary Gland: A Case Report. *Tumori*, **2007**, 93, 217-219	1.7	8
13	Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?. *Critical Reviews in Oncology/Hematology*, **2007**, 62, 1-8	7	2
12	Using specific cytotoxics with a targeted mind. *Breast*, **2007**, 16 Suppl 2, S120-6	3.6	31

11	Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). *European Journal of Cancer*, **2007**, 43, 725-35	7.5	38
10	Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?. *European Journal of Cancer*, **2007**, 43, 2270-8	7.5	20
9	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. *Molecular Cancer Therapeutics*, **2006**, 5, 2572-9	6.1	67
8	Chemotherapy for metastatic breast cancer. *Current Opinion in Obstetrics and Gynecology*, **2004**, 16, 37-41	1.4	18
7	Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. *Journal of Clinical Oncology*, **2003**, 21, 2045-7	2.2	59
6	Mortality associated with irinotecan plus bolus fluorouracil/leucovorin. *Journal of Clinical Oncology*, **2002**, 20, 1145-6	2.2	8
5	Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer. *Journal of Clinical Oncology*, **2002**, 20, 1954-5	2.2	6
4	Current status of HER2 testing. *Oncology*, **2002**, 63 Suppl 1, 25-32	3.6	42
3	Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. *Cancer Treatment Reviews*, **2002**, 28, 275-90	14.4	6
2	HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. *Clinical Cancer Research*, **2002**, 8, 1107-16	12.9	185
1	Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. *Journal of Clinical Oncology*, **2001**, 19, 3103-10	2.2	140